BRCA1 and neoplasm: A pre-specified, exploratory biomarker analysis from the ASCENT trial, evaluating the association between tumour Trop-2 expression and germline BRCA1/2 mutation status with clinical outcomes, suggested that sacituzumab govitecan benefits patients with previously treated MTNBC expressing high/medium Trop-2 compared with standard-of-care single-agent chemotherapy, and regardless of germline BRCA1/2 mutation status [94].